nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Bronchopneumonia—Liotrix—hypothyroidism	0.0176	0.144	CcSEcCtD
Bosutinib—Fluid retention—Liotrix—hypothyroidism	0.00365	0.0299	CcSEcCtD
Bosutinib—Dehydration—Levothyroxine—hypothyroidism	0.00353	0.0289	CcSEcCtD
Bosutinib—Dehydration—Dextrothyroxine—hypothyroidism	0.00353	0.0289	CcSEcCtD
Bosutinib—ABCB1—Levothyroxine—hypothyroidism	0.00323	0.28	CbGbCtD
Bosutinib—ABCB1—Liothyronine—hypothyroidism	0.00323	0.28	CbGbCtD
Bosutinib—ABCB1—Liotrix—hypothyroidism	0.00316	0.273	CbGbCtD
Bosutinib—Renal failure acute—Liotrix—hypothyroidism	0.00302	0.0247	CcSEcCtD
Bosutinib—Body temperature increased—Liothyronine—hypothyroidism	0.003	0.0246	CcSEcCtD
Bosutinib—Renal impairment—Liotrix—hypothyroidism	0.00293	0.024	CcSEcCtD
Bosutinib—Blood creatinine increased—Liotrix—hypothyroidism	0.00261	0.0214	CcSEcCtD
Bosutinib—Dehydration—Liotrix—hypothyroidism	0.0026	0.0212	CcSEcCtD
Bosutinib—Bronchitis—Liotrix—hypothyroidism	0.00232	0.019	CcSEcCtD
Bosutinib—Renal failure—Liotrix—hypothyroidism	0.00211	0.0173	CcSEcCtD
Bosutinib—Arthralgia—Dextrothyroxine—hypothyroidism	0.00195	0.0159	CcSEcCtD
Bosutinib—Arthralgia—Levothyroxine—hypothyroidism	0.00195	0.0159	CcSEcCtD
Bosutinib—CYP3A4—Levothyroxine—hypothyroidism	0.00194	0.168	CbGbCtD
Bosutinib—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.0017	0.0139	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.0017	0.0139	CcSEcCtD
Bosutinib—Dyspnoea—Levothyroxine—hypothyroidism	0.00166	0.0136	CcSEcCtD
Bosutinib—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00166	0.0136	CcSEcCtD
Bosutinib—Dysgeusia—Liotrix—hypothyroidism	0.00165	0.0135	CcSEcCtD
Bosutinib—Fatigue—Dextrothyroxine—hypothyroidism	0.00161	0.0132	CcSEcCtD
Bosutinib—Fatigue—Levothyroxine—hypothyroidism	0.00161	0.0132	CcSEcCtD
Bosutinib—Feeling abnormal—Levothyroxine—hypothyroidism	0.00154	0.0126	CcSEcCtD
Bosutinib—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00154	0.0126	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00153	0.0125	CcSEcCtD
Bosutinib—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00153	0.0125	CcSEcCtD
Bosutinib—Urticaria—Dextrothyroxine—hypothyroidism	0.00148	0.0121	CcSEcCtD
Bosutinib—Urticaria—Levothyroxine—hypothyroidism	0.00148	0.0121	CcSEcCtD
Bosutinib—Abdominal pain—Levothyroxine—hypothyroidism	0.00147	0.0121	CcSEcCtD
Bosutinib—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00147	0.0121	CcSEcCtD
Bosutinib—Body temperature increased—Levothyroxine—hypothyroidism	0.00147	0.0121	CcSEcCtD
Bosutinib—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00147	0.0121	CcSEcCtD
Bosutinib—Chest pain—Liotrix—hypothyroidism	0.00143	0.0117	CcSEcCtD
Bosutinib—Arthralgia—Liotrix—hypothyroidism	0.00143	0.0117	CcSEcCtD
Bosutinib—Oedema—Liotrix—hypothyroidism	0.00137	0.0112	CcSEcCtD
Bosutinib—Anaphylactic shock—Liotrix—hypothyroidism	0.00137	0.0112	CcSEcCtD
Bosutinib—Infection—Liotrix—hypothyroidism	0.00136	0.0111	CcSEcCtD
Bosutinib—Asthenia—Levothyroxine—hypothyroidism	0.00134	0.0109	CcSEcCtD
Bosutinib—Asthenia—Dextrothyroxine—hypothyroidism	0.00134	0.0109	CcSEcCtD
Bosutinib—Pruritus—Dextrothyroxine—hypothyroidism	0.00132	0.0108	CcSEcCtD
Bosutinib—Pruritus—Levothyroxine—hypothyroidism	0.00132	0.0108	CcSEcCtD
Bosutinib—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00128	0.0104	CcSEcCtD
Bosutinib—Diarrhoea—Levothyroxine—hypothyroidism	0.00128	0.0104	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00125	0.0102	CcSEcCtD
Bosutinib—Dyspnoea—Liotrix—hypothyroidism	0.00122	0.01	CcSEcCtD
Bosutinib—Decreased appetite—Liotrix—hypothyroidism	0.00119	0.00975	CcSEcCtD
Bosutinib—Vomiting—Levothyroxine—hypothyroidism	0.00119	0.0097	CcSEcCtD
Bosutinib—Vomiting—Dextrothyroxine—hypothyroidism	0.00119	0.0097	CcSEcCtD
Bosutinib—Fatigue—Liotrix—hypothyroidism	0.00118	0.00967	CcSEcCtD
Bosutinib—Rash—Dextrothyroxine—hypothyroidism	0.00118	0.00962	CcSEcCtD
Bosutinib—Rash—Levothyroxine—hypothyroidism	0.00118	0.00962	CcSEcCtD
Bosutinib—Dermatitis—Levothyroxine—hypothyroidism	0.00117	0.00961	CcSEcCtD
Bosutinib—Dermatitis—Dextrothyroxine—hypothyroidism	0.00117	0.00961	CcSEcCtD
Bosutinib—Headache—Dextrothyroxine—hypothyroidism	0.00117	0.00956	CcSEcCtD
Bosutinib—Headache—Levothyroxine—hypothyroidism	0.00117	0.00956	CcSEcCtD
Bosutinib—Feeling abnormal—Liotrix—hypothyroidism	0.00113	0.00925	CcSEcCtD
Bosutinib—Gastrointestinal pain—Liotrix—hypothyroidism	0.00112	0.00917	CcSEcCtD
Bosutinib—Nausea—Levothyroxine—hypothyroidism	0.00111	0.00906	CcSEcCtD
Bosutinib—Nausea—Dextrothyroxine—hypothyroidism	0.00111	0.00906	CcSEcCtD
Bosutinib—Urticaria—Liotrix—hypothyroidism	0.00109	0.00891	CcSEcCtD
Bosutinib—Body temperature increased—Liotrix—hypothyroidism	0.00108	0.00887	CcSEcCtD
Bosutinib—Abdominal pain—Liotrix—hypothyroidism	0.00108	0.00887	CcSEcCtD
Bosutinib—Asthenia—Liotrix—hypothyroidism	0.000984	0.00805	CcSEcCtD
Bosutinib—Pruritus—Liotrix—hypothyroidism	0.000971	0.00794	CcSEcCtD
Bosutinib—Diarrhoea—Liotrix—hypothyroidism	0.000939	0.00768	CcSEcCtD
Bosutinib—Dizziness—Liotrix—hypothyroidism	0.000907	0.00742	CcSEcCtD
Bosutinib—Vomiting—Liotrix—hypothyroidism	0.000872	0.00713	CcSEcCtD
Bosutinib—Rash—Liotrix—hypothyroidism	0.000865	0.00707	CcSEcCtD
Bosutinib—Dermatitis—Liotrix—hypothyroidism	0.000864	0.00707	CcSEcCtD
Bosutinib—Headache—Liotrix—hypothyroidism	0.000859	0.00703	CcSEcCtD
Bosutinib—Nausea—Liotrix—hypothyroidism	0.000815	0.00666	CcSEcCtD
Bosutinib—TBK1—thyroid gland—hypothyroidism	0.000472	0.000932	CbGeAlD
Bosutinib—MERTK—liver—hypothyroidism	0.000472	0.00093	CbGeAlD
Bosutinib—CSF1R—adrenal cortex—hypothyroidism	0.000471	0.000929	CbGeAlD
Bosutinib—RPS6KB1—adrenal gland—hypothyroidism	0.000471	0.000929	CbGeAlD
Bosutinib—RPS6KB1—blood—hypothyroidism	0.000471	0.000928	CbGeAlD
Bosutinib—ERBB3—female gonad—hypothyroidism	0.000471	0.000928	CbGeAlD
Bosutinib—BMPR2—cerebellum—hypothyroidism	0.00047	0.000926	CbGeAlD
Bosutinib—CSK—testis—hypothyroidism	0.00047	0.000926	CbGeAlD
Bosutinib—MAP2K2—female gonad—hypothyroidism	0.000469	0.000926	CbGeAlD
Bosutinib—ULK3—female gonad—hypothyroidism	0.000469	0.000926	CbGeAlD
Bosutinib—LCK—adrenal gland—hypothyroidism	0.000468	0.000923	CbGeAlD
Bosutinib—FGR—adrenal gland—hypothyroidism	0.000468	0.000923	CbGeAlD
Bosutinib—LCK—blood—hypothyroidism	0.000468	0.000923	CbGeAlD
Bosutinib—FGR—blood—hypothyroidism	0.000468	0.000923	CbGeAlD
Bosutinib—MAP2K5—heart—hypothyroidism	0.000467	0.000921	CbGeAlD
Bosutinib—CSNK1A1—testis—hypothyroidism	0.000467	0.00092	CbGeAlD
Bosutinib—AXL—adrenal gland—hypothyroidism	0.000466	0.000919	CbGeAlD
Bosutinib—EPHB3—cerebellum—hypothyroidism	0.000466	0.000919	CbGeAlD
Bosutinib—STK36—cerebellum—hypothyroidism	0.000466	0.000919	CbGeAlD
Bosutinib—MAP3K2—female gonad—hypothyroidism	0.000466	0.000919	CbGeAlD
Bosutinib—HCK—testis—hypothyroidism	0.000464	0.000915	CbGeAlD
Bosutinib—CLK1—testis—hypothyroidism	0.000464	0.000915	CbGeAlD
Bosutinib—IRAK1—thyroid gland—hypothyroidism	0.000463	0.000913	CbGeAlD
Bosutinib—MAP4K4—liver—hypothyroidism	0.000463	0.000913	CbGeAlD
Bosutinib—MAP3K7—female gonad—hypothyroidism	0.000462	0.000911	CbGeAlD
Bosutinib—ABL2—testis—hypothyroidism	0.000461	0.000909	CbGeAlD
Bosutinib—MERTK—cerebellum—hypothyroidism	0.000461	0.000909	CbGeAlD
Bosutinib—NUAK2—liver—hypothyroidism	0.00046	0.000906	CbGeAlD
Bosutinib—BCR—liver—hypothyroidism	0.00046	0.000906	CbGeAlD
Bosutinib—TBK1—female gonad—hypothyroidism	0.000456	0.0009	CbGeAlD
Bosutinib—PTK2—female gonad—hypothyroidism	0.000456	0.0009	CbGeAlD
Bosutinib—MAP3K12—liver—hypothyroidism	0.000456	0.0009	CbGeAlD
Bosutinib—CSF1R—heart—hypothyroidism	0.000456	0.000899	CbGeAlD
Bosutinib—CAMK2G—testis—hypothyroidism	0.000455	0.000898	CbGeAlD
Bosutinib—BMP2K—testis—hypothyroidism	0.000455	0.000898	CbGeAlD
Bosutinib—RPS6KB1—thyroid gland—hypothyroidism	0.000454	0.000896	CbGeAlD
Bosutinib—MAP4K4—cerebellum—hypothyroidism	0.000452	0.000892	CbGeAlD
Bosutinib—YES1—gonad—hypothyroidism	0.000452	0.000891	CbGeAlD
Bosutinib—LCK—thyroid gland—hypothyroidism	0.000452	0.000891	CbGeAlD
Bosutinib—FGR—thyroid gland—hypothyroidism	0.000452	0.000891	CbGeAlD
Bosutinib—LRRK2—testis—hypothyroidism	0.000451	0.00089	CbGeAlD
Bosutinib—AXL—thyroid gland—hypothyroidism	0.00045	0.000887	CbGeAlD
Bosutinib—EGFR—testis—hypothyroidism	0.00045	0.000887	CbGeAlD
Bosutinib—BCR—cerebellum—hypothyroidism	0.000449	0.000885	CbGeAlD
Bosutinib—NUAK2—cerebellum—hypothyroidism	0.000449	0.000885	CbGeAlD
Bosutinib—SLK—adrenal gland—hypothyroidism	0.000449	0.000885	CbGeAlD
Bosutinib—SLK—blood—hypothyroidism	0.000449	0.000885	CbGeAlD
Bosutinib—STK10—gonad—hypothyroidism	0.000448	0.000883	CbGeAlD
Bosutinib—IRAK1—female gonad—hypothyroidism	0.000448	0.000882	CbGeAlD
Bosutinib—MAP2K1—liver—hypothyroidism	0.000447	0.000882	CbGeAlD
Bosutinib—STK35—liver—hypothyroidism	0.000447	0.000882	CbGeAlD
Bosutinib—MAP3K12—cerebellum—hypothyroidism	0.000446	0.000879	CbGeAlD
Bosutinib—EPHB4—adrenal gland—hypothyroidism	0.000446	0.000879	CbGeAlD
Bosutinib—EPHB4—blood—hypothyroidism	0.000445	0.000878	CbGeAlD
Bosutinib—CSK—liver—hypothyroidism	0.000444	0.000876	CbGeAlD
Bosutinib—CSNK1A1—liver—hypothyroidism	0.000441	0.00087	CbGeAlD
Bosutinib—YES1—pituitary gland—hypothyroidism	0.000441	0.000869	CbGeAlD
Bosutinib—MAP2K5—cardiovascular system—hypothyroidism	0.000441	0.000869	CbGeAlD
Bosutinib—PTK2B—testis—hypothyroidism	0.00044	0.000867	CbGeAlD
Bosutinib—RPS6KB1—female gonad—hypothyroidism	0.000439	0.000866	CbGeAlD
Bosutinib—HCK—liver—hypothyroidism	0.000439	0.000865	CbGeAlD
Bosutinib—CLK1—liver—hypothyroidism	0.000439	0.000865	CbGeAlD
Bosutinib—EPHA2—adrenal gland—hypothyroidism	0.000437	0.000862	CbGeAlD
Bosutinib—EPHA2—blood—hypothyroidism	0.000437	0.000862	CbGeAlD
Bosutinib—STK35—cerebellum—hypothyroidism	0.000437	0.000861	CbGeAlD
Bosutinib—MAP2K1—cerebellum—hypothyroidism	0.000437	0.000861	CbGeAlD
Bosutinib—LCK—female gonad—hypothyroidism	0.000436	0.000861	CbGeAlD
Bosutinib—FGR—female gonad—hypothyroidism	0.000436	0.000861	CbGeAlD
Bosutinib—FYN—adrenal gland—hypothyroidism	0.000436	0.00086	CbGeAlD
Bosutinib—FYN—blood—hypothyroidism	0.000436	0.00086	CbGeAlD
Bosutinib—ABL2—liver—hypothyroidism	0.000436	0.000859	CbGeAlD
Bosutinib—TAOK3—pituitary gland—hypothyroidism	0.000435	0.000858	CbGeAlD
Bosutinib—AXL—female gonad—hypothyroidism	0.000435	0.000857	CbGeAlD
Bosutinib—SRC—gonad—hypothyroidism	0.000435	0.000857	CbGeAlD
Bosutinib—CSK—cerebellum—hypothyroidism	0.000434	0.000856	CbGeAlD
Bosutinib—SLK—thyroid gland—hypothyroidism	0.000433	0.000854	CbGeAlD
Bosutinib—CSNK1E—testis—hypothyroidism	0.000433	0.000853	CbGeAlD
Bosutinib—CSNK1A1—cerebellum—hypothyroidism	0.000431	0.00085	CbGeAlD
Bosutinib—CAMK2G—liver—hypothyroidism	0.00043	0.000849	CbGeAlD
Bosutinib—BMP2K—liver—hypothyroidism	0.00043	0.000849	CbGeAlD
Bosutinib—CSF1R—cardiovascular system—hypothyroidism	0.00043	0.000848	CbGeAlD
Bosutinib—EPHB4—thyroid gland—hypothyroidism	0.00043	0.000848	CbGeAlD
Bosutinib—CLK1—cerebellum—hypothyroidism	0.000428	0.000845	CbGeAlD
Bosutinib—LRRK2—liver—hypothyroidism	0.000427	0.000841	CbGeAlD
Bosutinib—MAP3K3—adrenal gland—hypothyroidism	0.000426	0.000841	CbGeAlD
Bosutinib—MAP4K5—adrenal gland—hypothyroidism	0.000426	0.000841	CbGeAlD
Bosutinib—MAP4K5—blood—hypothyroidism	0.000426	0.000841	CbGeAlD
Bosutinib—MAP3K3—blood—hypothyroidism	0.000426	0.000841	CbGeAlD
Bosutinib—SIK1—testis—hypothyroidism	0.000426	0.00084	CbGeAlD
Bosutinib—IRAK4—testis—hypothyroidism	0.000426	0.00084	CbGeAlD
Bosutinib—ABL2—cerebellum—hypothyroidism	0.000426	0.000839	CbGeAlD
Bosutinib—EGFR—liver—hypothyroidism	0.000425	0.000839	CbGeAlD
Bosutinib—EPHA2—thyroid gland—hypothyroidism	0.000422	0.000832	CbGeAlD
Bosutinib—EPHA4—testis—hypothyroidism	0.000422	0.000831	CbGeAlD
Bosutinib—FYN—thyroid gland—hypothyroidism	0.000421	0.00083	CbGeAlD
Bosutinib—CAMK2G—cerebellum—hypothyroidism	0.00042	0.000829	CbGeAlD
Bosutinib—BMP2K—cerebellum—hypothyroidism	0.00042	0.000829	CbGeAlD
Bosutinib—SLK—female gonad—hypothyroidism	0.000418	0.000825	CbGeAlD
Bosutinib—PDGFRB—adrenal cortex—hypothyroidism	0.000418	0.000824	CbGeAlD
Bosutinib—ERBB3—testis—hypothyroidism	0.000417	0.000823	CbGeAlD
Bosutinib—LRRK2—cerebellum—hypothyroidism	0.000417	0.000822	CbGeAlD
Bosutinib—ULK3—testis—hypothyroidism	0.000416	0.000821	CbGeAlD
Bosutinib—MAP2K2—testis—hypothyroidism	0.000416	0.000821	CbGeAlD
Bosutinib—PTK2B—liver—hypothyroidism	0.000416	0.00082	CbGeAlD
Bosutinib—EGFR—cerebellum—hypothyroidism	0.000415	0.000819	CbGeAlD
Bosutinib—EPHB4—female gonad—hypothyroidism	0.000415	0.000819	CbGeAlD
Bosutinib—MAP3K2—testis—hypothyroidism	0.000413	0.000815	CbGeAlD
Bosutinib—MAP4K5—thyroid gland—hypothyroidism	0.000411	0.000811	CbGeAlD
Bosutinib—MAP3K3—thyroid gland—hypothyroidism	0.000411	0.000811	CbGeAlD
Bosutinib—MAP3K7—testis—hypothyroidism	0.00041	0.000808	CbGeAlD
Bosutinib—CSNK1E—liver—hypothyroidism	0.000409	0.000806	CbGeAlD
Bosutinib—EPHA2—female gonad—hypothyroidism	0.000408	0.000804	CbGeAlD
Bosutinib—FYN—female gonad—hypothyroidism	0.000407	0.000802	CbGeAlD
Bosutinib—PTK2B—cerebellum—hypothyroidism	0.000406	0.000801	CbGeAlD
Bosutinib—TBK1—testis—hypothyroidism	0.000405	0.000798	CbGeAlD
Bosutinib—PTK2—testis—hypothyroidism	0.000405	0.000798	CbGeAlD
Bosutinib—PDGFRB—heart—hypothyroidism	0.000404	0.000797	CbGeAlD
Bosutinib—SIK1—liver—hypothyroidism	0.000403	0.000794	CbGeAlD
Bosutinib—IRAK4—liver—hypothyroidism	0.000403	0.000794	CbGeAlD
Bosutinib—CSNK1E—cerebellum—hypothyroidism	0.0004	0.000788	CbGeAlD
Bosutinib—MAP4K5—female gonad—hypothyroidism	0.000398	0.000784	CbGeAlD
Bosutinib—MAP3K3—female gonad—hypothyroidism	0.000398	0.000784	CbGeAlD
Bosutinib—IRAK1—testis—hypothyroidism	0.000397	0.000783	CbGeAlD
Bosutinib—ERBB3—liver—hypothyroidism	0.000395	0.000778	CbGeAlD
Bosutinib—YES1—adrenal gland—hypothyroidism	0.000394	0.000777	CbGeAlD
Bosutinib—YES1—blood—hypothyroidism	0.000394	0.000776	CbGeAlD
Bosutinib—MAP2K2—liver—hypothyroidism	0.000394	0.000776	CbGeAlD
Bosutinib—ULK3—liver—hypothyroidism	0.000394	0.000776	CbGeAlD
Bosutinib—SIK1—cerebellum—hypothyroidism	0.000393	0.000776	CbGeAlD
Bosutinib—IRAK4—cerebellum—hypothyroidism	0.000393	0.000776	CbGeAlD
Bosutinib—MAP3K2—liver—hypothyroidism	0.000391	0.000771	CbGeAlD
Bosutinib—STK10—adrenal gland—hypothyroidism	0.00039	0.00077	CbGeAlD
Bosutinib—CSF1R—gonad—hypothyroidism	0.00039	0.00077	CbGeAlD
Bosutinib—STK10—blood—hypothyroidism	0.00039	0.000769	CbGeAlD
Bosutinib—MAP2K5—pituitary gland—hypothyroidism	0.00039	0.000769	CbGeAlD
Bosutinib—RPS6KB1—testis—hypothyroidism	0.000389	0.000768	CbGeAlD
Bosutinib—EPHA4—cerebellum—hypothyroidism	0.000389	0.000768	CbGeAlD
Bosutinib—TAOK3—adrenal gland—hypothyroidism	0.000389	0.000767	CbGeAlD
Bosutinib—TAOK3—blood—hypothyroidism	0.000389	0.000766	CbGeAlD
Bosutinib—MAP3K7—liver—hypothyroidism	0.000387	0.000763	CbGeAlD
Bosutinib—FGR—testis—hypothyroidism	0.000387	0.000763	CbGeAlD
Bosutinib—LCK—testis—hypothyroidism	0.000387	0.000763	CbGeAlD
Bosutinib—AXL—testis—hypothyroidism	0.000386	0.00076	CbGeAlD
Bosutinib—ERBB3—cerebellum—hypothyroidism	0.000386	0.00076	CbGeAlD
Bosutinib—MAP2K2—cerebellum—hypothyroidism	0.000385	0.000758	CbGeAlD
Bosutinib—ULK3—cerebellum—hypothyroidism	0.000385	0.000758	CbGeAlD
Bosutinib—TBK1—liver—hypothyroidism	0.000383	0.000755	CbGeAlD
Bosutinib—PTK2—liver—hypothyroidism	0.000383	0.000755	CbGeAlD
Bosutinib—MAP3K2—cerebellum—hypothyroidism	0.000382	0.000753	CbGeAlD
Bosutinib—PDGFRB—cardiovascular system—hypothyroidism	0.000381	0.000752	CbGeAlD
Bosutinib—CSF1R—pituitary gland—hypothyroidism	0.000381	0.000751	CbGeAlD
Bosutinib—YES1—thyroid gland—hypothyroidism	0.00038	0.000749	CbGeAlD
Bosutinib—SRC—adrenal gland—hypothyroidism	0.000379	0.000747	CbGeAlD
Bosutinib—SRC—blood—hypothyroidism	0.000379	0.000747	CbGeAlD
Bosutinib—MAP3K7—cerebellum—hypothyroidism	0.000378	0.000746	CbGeAlD
Bosutinib—STK10—thyroid gland—hypothyroidism	0.000377	0.000743	CbGeAlD
Bosutinib—IRAK1—liver—hypothyroidism	0.000375	0.00074	CbGeAlD
Bosutinib—TAOK3—thyroid gland—hypothyroidism	0.000375	0.00074	CbGeAlD
Bosutinib—PTK2—cerebellum—hypothyroidism	0.000374	0.000737	CbGeAlD
Bosutinib—TBK1—cerebellum—hypothyroidism	0.000374	0.000737	CbGeAlD
Bosutinib—ABL1—adrenal cortex—hypothyroidism	0.000372	0.000734	CbGeAlD
Bosutinib—SLK—testis—hypothyroidism	0.000371	0.000732	CbGeAlD
Bosutinib—EPHB4—testis—hypothyroidism	0.000368	0.000727	CbGeAlD
Bosutinib—RPS6KB1—liver—hypothyroidism	0.000368	0.000726	CbGeAlD
Bosutinib—YES1—female gonad—hypothyroidism	0.000367	0.000724	CbGeAlD
Bosutinib—IRAK1—cerebellum—hypothyroidism	0.000367	0.000723	CbGeAlD
Bosutinib—LCK—liver—hypothyroidism	0.000366	0.000722	CbGeAlD
Bosutinib—FGR—liver—hypothyroidism	0.000366	0.000722	CbGeAlD
Bosutinib—SRC—thyroid gland—hypothyroidism	0.000366	0.000721	CbGeAlD
Bosutinib—AXL—liver—hypothyroidism	0.000365	0.000719	CbGeAlD
Bosutinib—STK10—female gonad—hypothyroidism	0.000364	0.000718	CbGeAlD
Bosutinib—TAOK3—female gonad—hypothyroidism	0.000362	0.000715	CbGeAlD
Bosutinib—EPHA2—testis—hypothyroidism	0.000361	0.000713	CbGeAlD
Bosutinib—FYN—testis—hypothyroidism	0.000361	0.000712	CbGeAlD
Bosutinib—ABL1—heart—hypothyroidism	0.00036	0.00071	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—hypothyroidism	0.00036	0.000709	CbGeAlD
Bosutinib—AXL—cerebellum—hypothyroidism	0.000356	0.000702	CbGeAlD
Bosutinib—SRC—female gonad—hypothyroidism	0.000353	0.000697	CbGeAlD
Bosutinib—MAP4K5—testis—hypothyroidism	0.000353	0.000695	CbGeAlD
Bosutinib—MAP3K3—testis—hypothyroidism	0.000353	0.000695	CbGeAlD
Bosutinib—SLK—liver—hypothyroidism	0.000351	0.000692	CbGeAlD
Bosutinib—MAP2K5—adrenal gland—hypothyroidism	0.000348	0.000687	CbGeAlD
Bosutinib—MAP2K5—blood—hypothyroidism	0.000348	0.000687	CbGeAlD
Bosutinib—EPHB4—liver—hypothyroidism	0.000348	0.000687	CbGeAlD
Bosutinib—PDGFRB—gonad—hypothyroidism	0.000346	0.000682	CbGeAlD
Bosutinib—SLK—cerebellum—hypothyroidism	0.000343	0.000676	CbGeAlD
Bosutinib—EPHA2—liver—hypothyroidism	0.000342	0.000674	CbGeAlD
Bosutinib—FYN—liver—hypothyroidism	0.000341	0.000673	CbGeAlD
Bosutinib—EPHB4—cerebellum—hypothyroidism	0.00034	0.000671	CbGeAlD
Bosutinib—CSF1R—adrenal gland—hypothyroidism	0.00034	0.000671	CbGeAlD
Bosutinib—CSF1R—blood—hypothyroidism	0.00034	0.000671	CbGeAlD
Bosutinib—ABL1—cardiovascular system—hypothyroidism	0.00034	0.00067	CbGeAlD
Bosutinib—PDGFRB—pituitary gland—hypothyroidism	0.000338	0.000666	CbGeAlD
Bosutinib—MAP2K5—thyroid gland—hypothyroidism	0.000336	0.000663	CbGeAlD
Bosutinib—MAP3K3—liver—hypothyroidism	0.000333	0.000657	CbGeAlD
Bosutinib—MAP4K5—liver—hypothyroidism	0.000333	0.000657	CbGeAlD
Bosutinib—FYN—cerebellum—hypothyroidism	0.000333	0.000657	CbGeAlD
Bosutinib—CSF1R—thyroid gland—hypothyroidism	0.000328	0.000647	CbGeAlD
Bosutinib—MAP3K3—cerebellum—hypothyroidism	0.000326	0.000642	CbGeAlD
Bosutinib—MAP4K5—cerebellum—hypothyroidism	0.000326	0.000642	CbGeAlD
Bosutinib—YES1—testis—hypothyroidism	0.000326	0.000642	CbGeAlD
Bosutinib—MAP2K5—female gonad—hypothyroidism	0.000325	0.000641	CbGeAlD
Bosutinib—STK10—testis—hypothyroidism	0.000323	0.000636	CbGeAlD
Bosutinib—TAOK3—testis—hypothyroidism	0.000321	0.000634	CbGeAlD
Bosutinib—CSF1R—female gonad—hypothyroidism	0.000317	0.000625	CbGeAlD
Bosutinib—SRC—testis—hypothyroidism	0.000313	0.000618	CbGeAlD
Bosutinib—ABL1—gonad—hypothyroidism	0.000308	0.000608	CbGeAlD
Bosutinib—YES1—liver—hypothyroidism	0.000308	0.000607	CbGeAlD
Bosutinib—STK10—liver—hypothyroidism	0.000305	0.000602	CbGeAlD
Bosutinib—TAOK3—liver—hypothyroidism	0.000304	0.000599	CbGeAlD
Bosutinib—PDGFRB—adrenal gland—hypothyroidism	0.000302	0.000595	CbGeAlD
Bosutinib—PDGFRB—blood—hypothyroidism	0.000302	0.000595	CbGeAlD
Bosutinib—ABL1—pituitary gland—hypothyroidism	0.000301	0.000593	CbGeAlD
Bosutinib—YES1—cerebellum—hypothyroidism	0.000301	0.000593	CbGeAlD
Bosutinib—STK10—cerebellum—hypothyroidism	0.000298	0.000588	CbGeAlD
Bosutinib—TAOK3—cerebellum—hypothyroidism	0.000297	0.000585	CbGeAlD
Bosutinib—SRC—liver—hypothyroidism	0.000296	0.000584	CbGeAlD
Bosutinib—PDGFRB—thyroid gland—hypothyroidism	0.000291	0.000574	CbGeAlD
Bosutinib—SRC—cerebellum—hypothyroidism	0.000289	0.000571	CbGeAlD
Bosutinib—MAP2K5—testis—hypothyroidism	0.000288	0.000568	CbGeAlD
Bosutinib—CSF1R—testis—hypothyroidism	0.000281	0.000555	CbGeAlD
Bosutinib—PDGFRB—female gonad—hypothyroidism	0.000281	0.000555	CbGeAlD
Bosutinib—MAP2K5—liver—hypothyroidism	0.000272	0.000537	CbGeAlD
Bosutinib—ABL1—adrenal gland—hypothyroidism	0.000269	0.00053	CbGeAlD
Bosutinib—ABL1—blood—hypothyroidism	0.000269	0.00053	CbGeAlD
Bosutinib—MAP2K5—cerebellum—hypothyroidism	0.000266	0.000525	CbGeAlD
Bosutinib—CSF1R—liver—hypothyroidism	0.000266	0.000524	CbGeAlD
Bosutinib—CSF1R—cerebellum—hypothyroidism	0.00026	0.000512	CbGeAlD
Bosutinib—ABL1—thyroid gland—hypothyroidism	0.000259	0.000512	CbGeAlD
Bosutinib—ABL1—female gonad—hypothyroidism	0.000251	0.000494	CbGeAlD
Bosutinib—PDGFRB—testis—hypothyroidism	0.000249	0.000492	CbGeAlD
Bosutinib—PDGFRB—liver—hypothyroidism	0.000236	0.000465	CbGeAlD
Bosutinib—PDGFRB—cerebellum—hypothyroidism	0.00023	0.000454	CbGeAlD
Bosutinib—ABL1—testis—hypothyroidism	0.000222	0.000438	CbGeAlD
Bosutinib—ABL1—liver—hypothyroidism	0.00021	0.000414	CbGeAlD
Bosutinib—ABL1—cerebellum—hypothyroidism	0.000205	0.000405	CbGeAlD
Bosutinib—CYP3A4—blood—hypothyroidism	0.000118	0.000233	CbGeAlD
Bosutinib—ABCB1—adrenal cortex—hypothyroidism	0.000116	0.000228	CbGeAlD
Bosutinib—ABCB1—heart—hypothyroidism	0.000112	0.000221	CbGeAlD
Bosutinib—ABCB1—cardiovascular system—hypothyroidism	0.000106	0.000208	CbGeAlD
Bosutinib—ABCB1—gonad—hypothyroidism	9.59e-05	0.000189	CbGeAlD
Bosutinib—ABCB1—pituitary gland—hypothyroidism	9.36e-05	0.000185	CbGeAlD
Bosutinib—CYP3A4—liver—hypothyroidism	9.23e-05	0.000182	CbGeAlD
Bosutinib—ABCB1—adrenal gland—hypothyroidism	8.36e-05	0.000165	CbGeAlD
Bosutinib—ABCB1—blood—hypothyroidism	8.36e-05	0.000165	CbGeAlD
Bosutinib—ABCB1—thyroid gland—hypothyroidism	8.07e-05	0.000159	CbGeAlD
Bosutinib—ABCB1—female gonad—hypothyroidism	7.8e-05	0.000154	CbGeAlD
Bosutinib—ABCB1—testis—hypothyroidism	6.91e-05	0.000136	CbGeAlD
Bosutinib—ABCB1—liver—hypothyroidism	6.54e-05	0.000129	CbGeAlD
Bosutinib—ABCB1—cerebellum—hypothyroidism	6.39e-05	0.000126	CbGeAlD
Bosutinib—CSK—Signaling Pathways—VAV3—hypothyroidism	4.62e-05	0.000129	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—AVP—hypothyroidism	4.61e-05	0.000128	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—AVP—hypothyroidism	4.61e-05	0.000128	CbGpPWpGaD
Bosutinib—SRC—Immune System—CLTC—hypothyroidism	4.59e-05	0.000128	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—POMC—hypothyroidism	4.59e-05	0.000128	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—VAV3—hypothyroidism	4.56e-05	0.000127	CbGpPWpGaD
Bosutinib—ERBB3—Disease—PRL—hypothyroidism	4.55e-05	0.000127	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—TSHB—hypothyroidism	4.54e-05	0.000126	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—TSHR—hypothyroidism	4.54e-05	0.000126	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TRH—hypothyroidism	4.5e-05	0.000125	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—SH2B3—hypothyroidism	4.45e-05	0.000124	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—AVP—hypothyroidism	4.45e-05	0.000124	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—SH2B3—hypothyroidism	4.45e-05	0.000124	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—IGF1—hypothyroidism	4.42e-05	0.000123	CbGpPWpGaD
Bosutinib—PTK2—Immune System—PRL—hypothyroidism	4.38e-05	0.000122	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—POMC—hypothyroidism	4.38e-05	0.000122	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—IYD—hypothyroidism	4.37e-05	0.000122	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—VAV3—hypothyroidism	4.36e-05	0.000121	CbGpPWpGaD
Bosutinib—YES1—Immune System—PRL—hypothyroidism	4.32e-05	0.00012	CbGpPWpGaD
Bosutinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	4.3e-05	0.00012	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—SH2B3—hypothyroidism	4.29e-05	0.00012	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TSHR—hypothyroidism	4.29e-05	0.000119	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TSHB—hypothyroidism	4.29e-05	0.000119	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CLTC—hypothyroidism	4.28e-05	0.000119	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TRH—hypothyroidism	4.24e-05	0.000118	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TSHB—hypothyroidism	4.23e-05	0.000118	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TSHR—hypothyroidism	4.23e-05	0.000118	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—IGF1—hypothyroidism	4.21e-05	0.000117	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—VAV3—hypothyroidism	4.21e-05	0.000117	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—POMC—hypothyroidism	4.2e-05	0.000117	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—VAV3—hypothyroidism	4.2e-05	0.000117	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—PRL—hypothyroidism	4.18e-05	0.000116	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CLTC—hypothyroidism	4.18e-05	0.000116	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—VAV3—hypothyroidism	4.13e-05	0.000115	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—PRL—hypothyroidism	4.1e-05	0.000114	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CLTC—hypothyroidism	4.09e-05	0.000114	CbGpPWpGaD
Bosutinib—PTK2—Immune System—VAV3—hypothyroidism	4.06e-05	0.000113	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—IGF1—hypothyroidism	4.04e-05	0.000113	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CLTC—hypothyroidism	4.03e-05	0.000112	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TSHB—hypothyroidism	4.01e-05	0.000112	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TSHR—hypothyroidism	4.01e-05	0.000112	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CLTC—hypothyroidism	4.01e-05	0.000112	CbGpPWpGaD
Bosutinib—YES1—Immune System—VAV3—hypothyroidism	4e-05	0.000111	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—VAV3—hypothyroidism	3.87e-05	0.000108	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—PRL—hypothyroidism	3.86e-05	0.000108	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—SH2B3—hypothyroidism	3.82e-05	0.000106	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—VAV3—hypothyroidism	3.79e-05	0.000106	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—POMC—hypothyroidism	3.79e-05	0.000105	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TSHB—hypothyroidism	3.78e-05	0.000105	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TSHR—hypothyroidism	3.78e-05	0.000105	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—SH2B3—hypothyroidism	3.77e-05	0.000105	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AVP—hypothyroidism	3.73e-05	0.000104	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ATP5O—hypothyroidism	3.72e-05	0.000104	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—VAV3—hypothyroidism	3.72e-05	0.000104	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TRH—hypothyroidism	3.7e-05	0.000103	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—POMC—hypothyroidism	3.67e-05	0.000102	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—PRL—hypothyroidism	3.61e-05	0.000101	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TRH—hypothyroidism	3.61e-05	0.000101	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—SH2B3—hypothyroidism	3.57e-05	9.95e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—VAV3—hypothyroidism	3.57e-05	9.95e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—PRL—hypothyroidism	3.56e-05	9.92e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TRH—hypothyroidism	3.54e-05	9.85e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—IGF1—hypothyroidism	3.53e-05	9.84e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—IGF1—hypothyroidism	3.5e-05	9.76e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TPO—hypothyroidism	3.5e-05	9.74e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—IGF1—hypothyroidism	3.49e-05	9.71e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TRH—hypothyroidism	3.48e-05	9.7e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CLTC—hypothyroidism	3.48e-05	9.69e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TRH—hypothyroidism	3.46e-05	9.65e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—IGF1—hypothyroidism	3.45e-05	9.61e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—POMC—hypothyroidism	3.44e-05	9.58e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PRL—hypothyroidism	3.43e-05	9.55e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—VAV3—hypothyroidism	3.42e-05	9.52e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—PRL—hypothyroidism	3.37e-05	9.4e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SH2B3—hypothyroidism	3.37e-05	9.37e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CLTC—hypothyroidism	3.35e-05	9.34e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—VAV3—hypothyroidism	3.34e-05	9.31e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PRL—hypothyroidism	3.3e-05	9.2e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PRL—hypothyroidism	3.3e-05	9.2e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TSHB—hypothyroidism	3.3e-05	9.19e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TSHR—hypothyroidism	3.3e-05	9.19e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—VAV3—hypothyroidism	3.29e-05	9.17e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PRL—hypothyroidism	3.29e-05	9.17e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AVP—hypothyroidism	3.29e-05	9.17e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	3.28e-05	9.13e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—PRL—hypothyroidism	3.22e-05	8.98e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AVP—hypothyroidism	3.22e-05	8.97e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TSHR—hypothyroidism	3.22e-05	8.97e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TSHB—hypothyroidism	3.22e-05	8.97e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PRL—hypothyroidism	3.21e-05	8.94e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—VAV3—hypothyroidism	3.2e-05	8.9e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PRL—hypothyroidism	3.18e-05	8.87e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—PRL—hypothyroidism	3.17e-05	8.84e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AVP—hypothyroidism	3.17e-05	8.84e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—VAV3—hypothyroidism	3.17e-05	8.84e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PRL—hypothyroidism	3.16e-05	8.79e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TSHB—hypothyroidism	3.15e-05	8.78e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TSHR—hypothyroidism	3.15e-05	8.78e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—POMC—hypothyroidism	3.12e-05	8.7e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—VAV3—hypothyroidism	3.12e-05	8.7e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PRL—hypothyroidism	3.12e-05	8.68e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TSHB—hypothyroidism	3.1e-05	8.64e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TSHR—hypothyroidism	3.1e-05	8.64e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TSHB—hypothyroidism	3.09e-05	8.6e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TSHR—hypothyroidism	3.09e-05	8.6e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AVP—hypothyroidism	3.08e-05	8.58e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—POMC—hypothyroidism	3.06e-05	8.54e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—POMC—hypothyroidism	3.06e-05	8.54e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AVP—hypothyroidism	3.06e-05	8.51e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—VAV3—hypothyroidism	3.06e-05	8.51e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—VAV3—hypothyroidism	3.06e-05	8.51e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—VAV3—hypothyroidism	3.05e-05	8.49e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PRL—hypothyroidism	3.04e-05	8.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TRH—hypothyroidism	3.01e-05	8.38e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IGF1—hypothyroidism	3e-05	8.36e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—VAV3—hypothyroidism	2.98e-05	8.31e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CLTC—hypothyroidism	2.97e-05	8.27e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—VAV3—hypothyroidism	2.97e-05	8.27e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—POMC—hypothyroidism	2.96e-05	8.24e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IGF1—hypothyroidism	2.95e-05	8.21e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IGF1—hypothyroidism	2.95e-05	8.21e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—VAV3—hypothyroidism	2.95e-05	8.21e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AVP—hypothyroidism	2.94e-05	8.2e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AVP—hypothyroidism	2.94e-05	8.2e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SH2B3—hypothyroidism	2.94e-05	8.19e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—VAV3—hypothyroidism	2.94e-05	8.18e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—PRL—hypothyroidism	2.93e-05	8.16e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—VAV3—hypothyroidism	2.92e-05	8.14e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PRL—hypothyroidism	2.92e-05	8.12e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TRH—hypothyroidism	2.9e-05	8.07e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—IGF1—hypothyroidism	2.87e-05	8e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SH2B3—hypothyroidism	2.87e-05	7.99e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IGF1—hypothyroidism	2.85e-05	7.93e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AVP—hypothyroidism	2.84e-05	7.91e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PRL—hypothyroidism	2.83e-05	7.9e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SH2B3—hypothyroidism	2.81e-05	7.83e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PRL—hypothyroidism	2.8e-05	7.79e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—VAV3—hypothyroidism	2.78e-05	7.73e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SH2B3—hypothyroidism	2.77e-05	7.7e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SH2B3—hypothyroidism	2.75e-05	7.66e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PRL—hypothyroidism	2.74e-05	7.64e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—IYD—hypothyroidism	2.69e-05	7.5e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TSHB—hypothyroidism	2.68e-05	7.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TSHR—hypothyroidism	2.68e-05	7.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AVP—hypothyroidism	2.68e-05	7.45e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PRL—hypothyroidism	2.65e-05	7.39e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—PRL—hypothyroidism	2.64e-05	7.36e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—VAV3—hypothyroidism	2.62e-05	7.3e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	2.59e-05	7.21e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—VAV3—hypothyroidism	2.59e-05	7.2e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TSHB—hypothyroidism	2.58e-05	7.2e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TSHR—hypothyroidism	2.58e-05	7.2e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TRH—hypothyroidism	2.57e-05	7.15e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—IGF1—hypothyroidism	2.54e-05	7.08e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—VAV3—hypothyroidism	2.54e-05	7.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PRL—hypothyroidism	2.53e-05	7.05e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AVP—hypothyroidism	2.53e-05	7.04e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PRL—hypothyroidism	2.5e-05	6.95e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AVP—hypothyroidism	2.49e-05	6.94e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—POMC—hypothyroidism	2.48e-05	6.9e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VAV3—hypothyroidism	2.45e-05	6.83e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—VAV3—hypothyroidism	2.44e-05	6.81e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PRL—hypothyroidism	2.44e-05	6.8e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SH2B3—hypothyroidism	2.39e-05	6.66e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IGF1—hypothyroidism	2.38e-05	6.63e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AVP—hypothyroidism	2.36e-05	6.58e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—PRL—hypothyroidism	2.34e-05	6.52e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VAV3—hypothyroidism	2.31e-05	6.43e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SH2B3—hypothyroidism	2.3e-05	6.41e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ATP5O—hypothyroidism	2.29e-05	6.38e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TSHR—hypothyroidism	2.29e-05	6.37e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TSHB—hypothyroidism	2.29e-05	6.37e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Biological oxidations—POMC—hypothyroidism	2.28e-05	6.36e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AVP—hypothyroidism	2.23e-05	6.2e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—POMC—hypothyroidism	2.19e-05	6.09e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PRL—hypothyroidism	2.18e-05	6.08e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—VAV3—hypothyroidism	2.16e-05	6.03e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PRL—hypothyroidism	2.16e-05	6.02e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TPO—hypothyroidism	2.15e-05	6e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—POMC—hypothyroidism	2.14e-05	5.96e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PRL—hypothyroidism	2.13e-05	5.93e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—POMC—hypothyroidism	2.11e-05	5.87e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PRL—hypothyroidism	2.08e-05	5.81e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IGF1—hypothyroidism	2.06e-05	5.73e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PRL—hypothyroidism	2.05e-05	5.72e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—POMC—hypothyroidism	2.05e-05	5.7e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PRL—hypothyroidism	2.04e-05	5.69e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SH2B3—hypothyroidism	2.04e-05	5.68e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	2.04e-05	5.67e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—POMC—hypothyroidism	2.03e-05	5.66e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IGF1—hypothyroidism	2.03e-05	5.65e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VAV3—hypothyroidism	2.02e-05	5.62e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VAV3—hypothyroidism	1.97e-05	5.49e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—POMC—hypothyroidism	1.96e-05	5.45e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—POMC—hypothyroidism	1.96e-05	5.45e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IGF1—hypothyroidism	1.95e-05	5.44e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AVP—hypothyroidism	1.94e-05	5.42e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VAV3—hypothyroidism	1.93e-05	5.37e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VAV3—hypothyroidism	1.9e-05	5.29e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AVP—hypothyroidism	1.9e-05	5.29e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VAV3—hypothyroidism	1.89e-05	5.26e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—POMC—hypothyroidism	1.89e-05	5.25e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IGF1—hypothyroidism	1.88e-05	5.24e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IGF1—hypothyroidism	1.88e-05	5.24e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AVP—hypothyroidism	1.86e-05	5.18e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AVP—hypothyroidism	1.83e-05	5.09e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AVP—hypothyroidism	1.82e-05	5.07e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IGF1—hypothyroidism	1.81e-05	5.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—POMC—hypothyroidism	1.78e-05	4.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PRL—hypothyroidism	1.77e-05	4.94e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PRL—hypothyroidism	1.71e-05	4.76e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—POMC—hypothyroidism	1.68e-05	4.68e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—POMC—hypothyroidism	1.66e-05	4.61e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VAV3—hypothyroidism	1.64e-05	4.57e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TSHB—hypothyroidism	1.62e-05	4.51e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IGF1—hypothyroidism	1.62e-05	4.5e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IGF1—hypothyroidism	1.59e-05	4.44e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VAV3—hypothyroidism	1.58e-05	4.4e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AVP—hypothyroidism	1.58e-05	4.4e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—POMC—hypothyroidism	1.57e-05	4.37e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AVP—hypothyroidism	1.52e-05	4.24e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PRL—hypothyroidism	1.51e-05	4.21e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IGF1—hypothyroidism	1.51e-05	4.21e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—POMC—hypothyroidism	1.48e-05	4.12e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3C2A—hypothyroidism	1.44e-05	4.02e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IGF1—hypothyroidism	1.42e-05	3.96e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VAV3—hypothyroidism	1.4e-05	3.9e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AVP—hypothyroidism	1.35e-05	3.76e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—POMC—hypothyroidism	1.29e-05	3.6e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—POMC—hypothyroidism	1.26e-05	3.51e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IGF1—hypothyroidism	1.24e-05	3.46e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—POMC—hypothyroidism	1.23e-05	3.44e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—POMC—hypothyroidism	1.22e-05	3.39e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF1—hypothyroidism	1.21e-05	3.38e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—SLC5A5—hypothyroidism	1.21e-05	3.37e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—POMC—hypothyroidism	1.21e-05	3.37e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF1—hypothyroidism	1.19e-05	3.31e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF1—hypothyroidism	1.17e-05	3.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF1—hypothyroidism	1.16e-05	3.24e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—POMC—hypothyroidism	1.05e-05	2.93e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—POMC—hypothyroidism	1.01e-05	2.82e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1—hypothyroidism	1.01e-05	2.81e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TSHB—hypothyroidism	9.97e-06	2.78e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1—hypothyroidism	9.73e-06	2.71e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—POMC—hypothyroidism	8.96e-06	2.5e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	8.89e-06	2.48e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—hypothyroidism	8.62e-06	2.4e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—hypothyroidism	7.46e-06	2.08e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—hypothyroidism	6.34e-06	1.77e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—hypothyroidism	3.91e-06	1.09e-05	CbGpPWpGaD
